Abstract
Monoclonal antibodies (mAbs) are novel, effective therapeutics for the treatment of inadequately controlled severe asthma. Knowledge of the anaphylaxis risks related to different mAbs is essential for their appropriate and safe administration. This study aimed to evaluate the associations between different mAbs and anaphylactic reactions by applying statistical approaches to pharmacovigilance data. This was a retrospective study using data from the US Food and Drug Administration Adverse Event Reporting System database from January 2004 to September 2020. A total of 2006 reports of anaphylaxis related to benralizumab, dupilumab, mepolizumab, omalizumab, and reslizumab were obtained through data mining. The clinical characteristics of the cases were analyzed, and the risk signals of anaphylactic reactions and corresponding outcomes were investigated in the five mAbs. The patients were mainly young and middle-aged adults, with markedly more women than men. Omalizumab, benralizumab, reslizumab, and mepolizumab showed positive signals for anaphylaxis, while only dupilumab showed a negative signal. The risk of initial or prolonged hospitalization due to anaphylaxis was significantly higher in the benralizumab group than in the omali...Continue Reading
References
Feb 7, 2002·Pharmacoepidemiology and Drug Safety·S J EvansS Davis
May 10, 2002·Pharmacoepidemiology and Drug Safety·Eugène P van PuijenbroekAntoine C G Egberts
Jun 20, 2002·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Ana SzarfmanRobert T O'Neill
Jul 5, 2003·The Annals of Pharmacotherapy·Manfred Hauben
Aug 23, 2005·Expert Opinion on Drug Safety·Manfred HaubenEugene P Van Puijenbroek
Dec 29, 2005·Statistics in Medicine·G Niklas NorénI Ralph Edwards
Oct 16, 2007·The Journal of Allergy and Clinical Immunology·Susan L LimbBadrul A Chowdhury
May 22, 2010·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·Carlos IribarrenMark D Eisner
Jul 30, 2010·Pharmacoepidemiology and Drug Safety·Nobuhiro Ooba, Kiyoshi Kubota
May 3, 2011·The Journal of Allergy and Clinical Immunology·Linda CoxLawrence Schwartz
Jun 13, 2014·The World Allergy Organization Journal·F Estelle R SimonsMargitta Worm
May 13, 2015·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·Rachel G HarrisonWilliam H Yang
Jan 25, 2017·Expert Opinion on Drug Safety·E LeungJ M FitzGerald
Aug 12, 2017·The Journal of Allergy and Clinical Immunology·Phillip L LiebermanDale T Umetsu
Mar 1, 2018·Expert Opinion on Drug Safety·Mario CazzolaPaola Rogliani
Mar 9, 2018·The Journal of Allergy and Clinical Immunology·Ghislaine Annie C IsabweMariana Castells
Oct 6, 2018·Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology·Guillaume PouesselLuciana K Tanno
Aug 14, 2019·The Journal of Allergy and Clinical Immunology. in Practice·J Christian VirchowMario Castro
Nov 18, 2019·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·Angela Duff Hogan, Jonathan A Bernstein
Jan 21, 2020·Expert Review of Respiratory Medicine·Georgios HillasAndriana I Papaioannou
Jan 30, 2020·Expert Review of Clinical Immunology·Kim Jackson, Sami L Bahna
Jun 17, 2020·Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology·Koichi JingoKazuhisa Takahashi
Sep 30, 2020·The Journal of Allergy and Clinical Immunology. in Practice·Roger J YuCosby A Stone
Dec 4, 2020·JAMA : the Journal of the American Medical Association·Michelle M CloutierMichael Schatz
Jan 30, 2021·The World Allergy Organization Journal·M CaminatiG Senna